A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies cediranib maleate in combination with olaparib in treating
patients with solid tumors that have spread to other parts of the body (advanced/metastatic)
or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung
cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor
more sensitive to olaparib.